Sino-American biotech BeiGene (BGNE; HKEX) has announced results for the first quarter of 2024 and business highlights, sending it shares up 3% to 138.46 renminbi.
Revenue for the three months was $752 million, compared to $448 million in the same period of 2023, driven primarily by growth in Brukinsa (zanubrutinib) product sales in the U.S. and Europe of 153% and 243% respectively.
Product Revenue for the three months ended March 31, 2024,
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze